Page 5 - Inflarx Commitment Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflarx commitment program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflarx Commitment Program Today - Breaking & Trending Today

InflaRx (NASDAQ:IFRX) Raised to "Outperform" at Lifesci Capital

Lifesci Capital upgraded shares of InflaRx (NASDAQ:IFRX – Get Rating) from a market perform rating to an outperform rating in a research report released on Wednesday, Benzinga reports. Separately, HC Wainwright reissued a buy rating and set a $6.00 price target on shares of InflaRx in a research report on Thursday, March 23rd. Four analysts […] ....

Niels Christoph Riedemann , Renfeng Guo , Nicolas Fulpius , Raymond James Financial Services Advisors Inc , Raymond James Associates , Group One Trading , Kestra Advisory Services , Jpmorgan Chase Co , Lifesci Capital , Get Rating , James Financial Services Advisors , Advisory Services , Raymond James , Inflarx Daily , Nasdaq Ifrx ,

InflaRx (NASDAQ:IFRX) Raised to "Outperform" at Lifesci Capital

Lifesci Capital upgraded shares of InflaRx (NASDAQ:IFRX – Get Rating) from a market perform rating to an outperform rating in a research report sent to investors on Wednesday, Benzinga reports. Separately, HC Wainwright reissued a buy rating and set a $6.00 price target on shares of InflaRx in a research report on Thursday, March 23rd. […] ....

Renfeng Guo , Niels Christoph Riedemann , Nicolas Fulpius , Virtu Financial , Raymond James Associates , Kestra Advisory Services , Inflarx Company Profile , Group One Trading , Jpmorgan Chase Co , Lifesci Capital , Get Rating , Advisory Services , Raymond James , Inflarx Daily , Nasdaq Ifrx ,

InflaRx (NASDAQ:IFRX) Stock Rating Upgraded by Lifesci Capital

InflaRx (NASDAQ:IFRX – Get Rating) was upgraded by research analysts at Lifesci Capital from a “market perform” rating to an “outperform” rating in a research note issued to investors on Wednesday, Benzinga reports. Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of InflaRx in a research note on […] ....

Nicolas Fulpius , Niels Christoph Riedemann , Renfeng Guo , Kestra Advisory Services , Virtu Financial , Jpmorgan Chase Co , Raymond James Associates , Group One Trading , Get Rating , Lifesci Capital , Advisory Services , Raymond James , Inflarx Daily , Nasdaq Ifrx ,

InflaRx Covid-19 Drug Welcomes an FDA Win; Pardes Bio Throws In the Towel

The FDA granted emergency use authorization to an InflaRx antibody drug that treats hospitalized Covid-19 patients. But Pardes Bioscience’s coronavirus journey is ending following the Phase 2 failure of an antiviral that was expected to compete with Pfizer’s Paxlovid. ....

Inflarx Gohibic , Pardes Biosciences , Eli Lilly , Germany Based Inflarx , California Based Pardes , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Ealth And Wellness , Mployee Wellness Programs , Hanghai Innovation Center ,

InflaRx Shares Soar 40% on FDA Emergency Use Authorization of Gohibic for Covid-19

By Denny Jacob

InflaRx NV shares were on pace Wednesday for its best three-day stretch on record, a day after Gohibic, a monoclonal anti-human complement factor C5a antibody it is developing,. | April 5, 2023 ....

Denny Jacob , Niels Riedemann , European Committee For Medicinal Products Human , Drug Administration , European Medicines Agency , European Committee , Medicinal Products , Human Use , European Medicines , Executive Niels Riedemann , Dow Jones , Inflarxnv Stock Exchange , Press Release , S Ifrx Nl0012661870 ,